E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pts with type 1 diabetes mellitus based on the WHO criteria, at least 8 years old, used an insulin pen device to inject at least 4 insulin doses/day for at least 2 months prior to the study and currently have at least 3 prandial injections/day with a short-acting insulin/insulin analogue; HbA1c ≥ 8% at Visit 1; capability of self-injecting insulin with HumaPen Memoir or HumaPen Luxura and usage of a disease-related documentation tool (patient diary); ability to give informed consent |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10012602 |
E.1.2 | Term | Diabetes mellitus (incl subtypes) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections in children, adolescents and adults with type 1 diabetes, achieves superior glycemic control, as measured by the difference in change in HbA1c, when compared to the conventional HumaPen Luxura without memory function. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are as follows: • to assess the proportion of patients achieving HbA1c targets of ≤ 7.5% and ≤ 7.0% at Week 24 in both treatment groups • to monitor safety of the pen devices in this patient population, as assessed by adverse events and complaints • to monitor hypoglycemia and hyperglycemia in both treatment arms • to evaluate patient acceptance of the HumaPen Memoir and HumaPen Luxura as insulin injection devices, as assessed by the "Insulin Delivery System Questionnaire" (IDSQ). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
[1] Present with type 1 diabetes mellitus based on the World Health Organization (WHO) criteria (Bennett 1991). [2] Are at least 8 years old at the date of Visit 1. [3] Have used an insulin pen device to inject at least 4 insulin doses per day for at least 2 months immediately prior to the study. [4] Are currently receiving at least 3 prandial injections per day with a short-acting insulin or insulin analogue. [5] Have inadequate glycemic control evidenced by HbA1c equal to or above 8% at Visit 1. [6] In the investigator’s opinion, patients (and parents/legal representatives, if applicable), are well-motivated to improve their glycemic control. [7] As determined by the investigator, patients are capable of, and willing to • self-inject insulin with the HumaPen Memoir or HumaPen Luxura, • use a disease-related documentation tool (patient diary). [8] Inclusion criterion [8] applies to female patients of child-bearing potential (not surgically sterilized and between menarche and one year post menopause) only; they must • not be breastfeeding • test negative for pregnancy at the time of screening based on a urine or serum test, • intend not to become pregnant during the study, • agree to use a highly reliable method of birth control (failure rate less than 1% per year; sexual abstinence; vasectomized partner) during the study. [9] Have provided written informed consent/assent to participate in this study, according to local regulations (see Section 9.1). |
|
E.4 | Principal exclusion criteria |
[10] Are currently using a continuous subcutaneous insulin infusion therapy (CSII) [11] Are receiving insulin treatment with pre-mixed insulin preparations [12] Have impaired vision that prevents them from operating the HumaPen Memoir without assistance . [13] Have any other condition (including known drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol. [14] Have previously completed or withdrawn from this study after providing written informed consent. [15] Are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. [16] Are Lilly employees. [17] Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
This is a A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults with Type 1 Diabetes: Novel Pen with Memory Function (HumaPen® Memoir) vs. Conventional Pen without Memory Function (HumaPen® Luxura)
End of study (trial) is defined as the date of the last visit or last scheduled procedure at the last site shown in the Study Schedule for the last active subject in the study.
The criteria for enrollment must be followed explicitly. If a patient who does not meet enrollment criteria is inadvertently enrolled, that patient is discontinued from the study, and Lilly or its designee must be contacted. In addition, patients will be discontinued from the study in the following circumstances. • If Exclusion Criterion [10], [11], [12], or [13] is observed, or develops, after entry or enrollment. In this case, the patient will be discontinued from the study at the next visit or sooner in the event of a safety exclusion criterion. • A female patient becomes pregnant. • The investigator decides that the patient should be withdrawn. If this decision is made because of a serious adverse event or a clinically significant laboratory value, the study drug is to be discontinued and appropriate measures are to be taken. Lilly or its designee is to be alerted immediately. Refer to Section 6.3, Safety Evaluations. • The patient or attending physician requests that the patient be withdrawn from the study. • The patient, for any reason, can no longer be treated with Lilly insulin or the HumaPen Memoir / Luxura. In this case, discontinuation from the study occurs prior to introduction of the new insulin or injection device. • The investigator or Lilly, for any reason, stops the study or stops the patient's participation in the study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 17 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 5 |